Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress [Yahoo! Finance]
Zenas BioPharma, Inc. (ZBIO)
Company Research
Source: Yahoo! Finance
Zenas BioPharma started trading on the NASDAQ in September 2024. The company closed an upsized initial public offering of 15.22 million shares at $17 per share, raising approximately $258.7 million in gross proceeds The company's lead program obexelimab concluded enrollment in the Phase 3 INDIGO trial for immunoglobulin-G4-Related Disease (IgG4-RD). Topline data is expected by the end of 2025 The company also initiated the Phase 2 MoonStone trial for Relapsing Multiple Sclerosis (MS) and the Phase 2 SunStone trial for Systemic Lupus Erythematosus (SLE). Also Read: PTC Therapeutics Reveals New Sepiapterin Data From Phase 3 Study In Patients With Inherited Disorder, FDA Decision Expected In July 12-week primary endpoint results from the MoonStone trial are expected in the third quarter of 2025, and topline data from the SunStone trial are expected in the first half of 2026. Analyst Martin Fan writes that obexelimab is a CD19 mAb that suppresses B cells, rather than eliminatin
Show less
Read more
Impact Snapshot
Event Time:
ZBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZBIO alerts
High impacting Zenas BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
ZBIO
News
- Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Zenas BioPharma (NASDAQ:ZBIO) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Zenas BioPharma (NASDAQ:ZBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus [Yahoo! Finance]Yahoo! Finance
ZBIO
Earnings
- 11/12/25 - Miss
ZBIO
Sec Filings
- 12/19/25 - Form S-8
- 12/15/25 - Form 8-K
- 11/14/25 - Form SCHEDULE
- ZBIO's page on the SEC website